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Abstract Dystrophic muscles suVer from enhanced oxi-
dative stress. We have investigated whether administration
of an antioxidant, epigallocatechin-3-gallate (EGCG), a
component of green tea, reduces their oxidative stress and
pathophysiology in mdx mice, a mild phenotype model
of human Duchenne-type muscular dystrophy. EGCG
(5 mg/kg body weight in saline) was injected subcutaneously
4£ a week into the backs of C57 normal and dystrophin-
deWcient mdx mice for 8 weeks after birth. Saline was
injected into normal and mdx controls. EGCG had almost
no observable eVects on normal mice or on the body
weights of mdx mice. In contrast, it produced the following
improvements in the blood chemistry, muscle histology,
and electrophysiology of the treated mdx mice. First, the
activities of serum creatine kinase were reduced to normal
levels. Second, the numbers of Xuorescent lipofuscin gran-
ules per unit volume of soleus and diaphragm muscles were
signiWcantly decreased by about 50% compared to the num-
bers in the corresponding saline-treated controls. Third, in
sections of diaphragm and soleus muscles, the relative area
occupied by histologically normal muscle Wbres increased
signiWcantly 1.5- to 2-fold whereas the relative areas of
connective tissue and necrotic muscle Wbres were substan-
tially reduced. Fourth, the times for the maximum tetanic
force of soleus muscles to fall by a half increased to almost
normal values. Fifth, the amount of utrophin in diaphragm
muscles increased signiWcantly by 17%, partially compen-
sating for the lack of dystrophin expression.
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Introduction
Duchenne muscular dystrophy (DMD) is a human X-linked
progressive muscle-wasting disease. It is caused by muta-
tions and deletions in the dystrophin gene, resulting in the
lack of full-length dystrophin molecules in the sarcolemma
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490 Histochem Cell Biol (2008) 129:489–501(reviewed by Khurana and Davies 2003). Dystrophin stabi-
lises the sarcolemma during muscle contraction by interact-
ing with the intracellular actin cytoskeleton and the
extracellular matrix through the dystrophin-associated gly-
coprotein complex in the sarcolemma (Blake et al. 2002;
Dalkilic and Kunkel 2003; Ervasti 2007).
Previously, we found that dystrophin-deWcient muscles
of DMD patients and mdx mice exhibit oxidative stress
because they are unable to destroy, via superoxide dismu-
tase- and catalase-mediated pathways, all the reactive oxy-
gen species produced from side reactions of oxygen
metabolism. Thus, they suVer from more oxidative damage
than age-matched normal controls, leading to the formation
of end products of peroxidation such as lipofuscin and 8-
oxoguanine in DNA (Nakae et al. 2001, 2004, 2005,
2006a). Many authors have attested to the role of oxidative
stress in causing or modulating, for example, muscle cell
atrophy, survival and regeneration (e.g. Barker and Traber
2007; Narciso et al. 2007; Zaccagnini et al. 2007). Conse-
quently, we have hypothesized, as others have done (Disat-
nik et al. 1998, 2000; Rando 2002; Rando et al. 1998; Burdi
et al. 2006; Dudley et al. 2006; Messina et al. 2006; Tidball
and Wehling-Henricks 2007; Williams and Allen 2007),
that oxidative stress is a major contributing factor in the
pathology of DMD.
In this paper, we report that subcutaneous injection from
birth of a low dose of the principal polyphenol antioxidant
present in green tea, (¡)-epigallocatechin-3-gallate (EGCG),
reduces the oxidative stress in dystrophin-deWcient muscles
of mdx mice, a well-established experimental model of DMD
(BulWeld et al. 1984). It also signiWcantly improves the histo-
logy and function of their soleus and diaphragm muscles. A
preliminary summary of this work has been published else-
where (Nakae et al. 2006b, 2007). Whilst our investigation
was in progress, Ruegg and his colleagues reported that feed-
ing mdx mice with either a green tea extract or EGCG in food
pellets improved the histological features and function of
extensor digitorum longus muscle but not soleus muscle
(Buetler et al. 2002; Dorchies et al. 2006).
A number of other compounds have been reported to
improve the physiological function of dystrophic muscles.
They include heregulin (Krag et al. 2004), L-arginine (Barton
et al. 2005; Voisin et al. 2005), and the glucocorticoids meth-
ylprednisolone (Passaquin et al. 1993; Courdier-Fruh et al.
2002) and dexamethasone (Pasquini et al. 1995), all of which
increase the levels of utrophin, an autosomal gene product
with high homology to dystrophin (Khurana and Davies
2003; Chakkalakal et al. 2005; Hirst et al. 2005; Miura and
Jasmin 2006). We have, therefore, also investigated whether
EGCG administration gives rise to increased utrophin expres-
sion as this may throw additional light on the mechanisms
responsible for the eVects of EGCG on dystrophic muscle.
Materials and methods
EGCG treatment and tissues
All animal experiments were performed according to pro-
cedures approved by the animal care committee of the Uni-
versity of Tokushima Graduate School. Normal C57BL/10-
SnSlc mice (abbreviated as C57 mice) and dystrophic
C57BL/10-mdx Jic mice (abbreviated as mdx mice) were
obtained from Japan SLC (Hamamatsu, Japan) and CLEA
Japan (Tokyo, Japan), respectively. They were fed with a
standard laboratory diet (CE-2; CLEA Japan) and given
free access to tap water, and housed in a room with 12 h
light/dark cycles at 22–23°C. Males and females of the
same strain were mated at the age of 10 weeks. Littermate
neonates were divided into two groups, a test and a control
group. (¡)-Epigallocatechin-3-gallate (EGCG; purity ¸
95%), extracted from green tea, was purchased from
Sigma-Aldrich Japan, Tokyo, and dissolved in sterile phys-
iological saline (Otuka Pharmaceutical, Tokushima, Japan)
at a concentration of 0.4 mg/ml, Wltered through a sterile
syringe with a 0.20 m pore Wlter (DISMIC-13cp; Advan-
tec Toyo, Tokyo, Japan), stored at 4°C, and used within
10 days after preparation. Calculated volumes of the
Wltered EGCG solution, corresponding to a dose of 5 mg
EGCG/kg body weight, were injected subcutaneously,
using either autoclaved microsyringes (Hamilton, Reno,
Nevada, USA) or sterile disposable syringes into the backs
of both mdx and normal C57 mice, 4£ a week for 8 weeks
from either the day of birth or a day after birth. As controls,
mdx and normal mice were injected with physiological
saline only. At the end of the treatment schedule, all mice
were sacriWced by cervical dislocation. Their diaphragm,
soleus and lingual muscles, livers and kidneys were
removed. The total numbers of mice used in the present
study were 8, 13: C57 + saline; 13, 15: C57 + EGCG;
9, 9: mdx + saline; 8, 11: mdx + EGCG.
Serum creatine kinase (CK) activity
Blood samples were taken from the hearts of 8-week-old
mice under chloroform anaesthesia and centrifuged at
3,000 rpm for 10 min to obtain sera. The activities of mus-
cle-derived CK in the test and control samples were mea-
sured simultaneously at 37°C by Mitsubishikagaku
Biochemical Laboratories (Tokyo, Japan) using a routine
UV-method (Gerhardt and WulV 1983) and commercial kit
(CicaLiquid CK; Kanto Chemical, Tokyo, Japan), with cre-
atine phosphate as the substrate. The numbers of mice used
for the activity measurements were 3, 1: C57 + saline;
3, 3: C57 + EGCG; 4, 3: mdx + saline; 5, 4:
mdx + EGCG.123
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The levels of oxidative stress in three untreated and three
treated male mdx mice were determined by counting the
number of autoXuorescent lipofuscin granules or clumps
accumulated focally in frozen, 7 m-thick, cross-sections
of diaphragm and soleus muscles as described previously
(Nakae et al. 2004). Optical slices of each section excited
simultaneously at 488 and 568 nm were captured at 16
consecutive confocal planes using a confocal laser-scan-
ning microscope (TCS NT; Leica, Heidelberg, Germany)
and used to reconstruct a Xuorescent image of the section.
Assuming that the thickness of the sections was uniformly
7 m, the numbers of lipofuscin granules or clumps per
mm3 were calculated. The muscles of the normal mice
controls were not examined as previously we found that
their lipofuscin content was negligible (Nakae et al.
2004).
Histology
Frozen transverse sections, 7 m thick, of diaphragm and
soleus muscles, tongue, liver and kidney were prepared as
described previously (Nakae et al. 2004). The sections were
Wxed in 1:1 v/v acetone–methanol at 4°C for 5 min, stained
with Haematoxylin solution (DakoCytomation, Kyoto,
Japan) followed by 0.25% Eosin Y (Merck, Tokyo, Japan)
in 79% ethanol containing 0.5% acetic acid, and mounted
in Histomount (Zymed Laboratories, South San Francisco,
California, USA). Images of the sections were captured
under a Zeiss Axioskop microscope (Oberkochen, Ger-
many) Wtted with a Fujix digital camera (HC-2500 3CCD;
Fuji Photo Film, Tokyo, Japan) using Photograb-2500 ver-
sion 1.0 software (Fuji Photo Film).
The total areas occupied respectively by mature muscle
Wbres with peripheral nuclei (i.e. histologically normal
Wbres), muscle Wbres with central nuclei (regenerating mus-
cle Wbres), and necrotic muscle Wbres, were measured in
sections of soleus and diaphragm muscles using a personal
computer and ImageJ version 1.37v software (NIH,
Bethesda, Maryland, USA). The necrotic Wbres were identi-
Wed as degenerated Wbres with diVusely-stained eosino-
philic myoWbrils and broken sarcolemmas, and were often
associated with macrophages. The total tissue areas of each
section were also measured. The total area of connective
tissue in each section was calculated by subtracting the sum
of the areas of the three muscle Wbre forms from the total
tissue section areas. The relative areas of the muscle Wbre
forms and connective tissue were expressed as percentages
of the total tissue area. The total observed cross-section
areas of diaphragm muscle were 1.79 £ 10¡2 cm2
in mdx + saline  mice (n = 3) and 2.13 £ 10¡2 cm2 in
mdx + EGCG  (n = 3) mice. The corresponding areas in
soleus muscle were 2.81 £ 10¡2 and 3.10 £ 10¡2 cm2,
respectively.
Contraction recording and analysis
Freshly dissected soleus muscle was stimulated directly by
an electrical Weld generated between two parallel electrodes
connected to a stimulator SEN-3201 and bath drive ampli-
Wer SEG-3101 (Nihon Kohden, Tokyo, Japan), according to
the method of Xiao et al. (2000) with modiWcations. The
muscle length was adjusted until a single stimulus pulse or
a train of pulses elicited the maximum force during a twitch
or tetanus under isometric conditions. Rectangular pulses
[0.5 ms delay, 0.5 ms duration, 500 ms interval time (2 Hz)
and 4 V] were applied to elicit twitch contractions for
2 min. The interval time was then changed to 50 ms
(20 Hz) to elicit fused contractions (complete tetanus).
All experiments were performed at 37°C. The tetanic
force (muscle contraction) was recorded as a function of
time in a physiological solution (5 mM HEPES buVer, pH
7.4, containing 150 mM NaCl, 4 mM KCl, 1.8 mM CaCl2,
1 mM MgCl2 and 5.6 mM glucose) in a magnus tube
(Kishimoto Medical Instruments, Kyoto, Japan). A per-
sonal computer (Macintosh Server G3; Apple Japan,
Tokyo, Japan), digital chart recorder MacLab 8e (Bio
Research Centre, Nagoya, Japan), transducer UM-203 and
detector AP-5 (Kishimoto Medical Instruments) were used
for data acquisition. The data were analysed using MacLab
Chart version 3.5.2/s software (Bio Research Centre). The
speciWc tetanic force was determined as the maximal force
per cross sectional area (CSA). The CSA was calculated
from the wet weight and length of the muscle assuming a
muscle density of 1.056 g/cm3. The mean time (T1/2max)
from when the tetanic force Wrst reaches a maximum to
when the force falls by a half was determined from the teta-
nic force–contraction time curves. The numbers of mice
used in the contraction analyses were 6, 0 C57 + saline;
6, 1 C57 + EGCG; 6, 2 mdx + saline; 7, 2
mdx + EGCG.
Utrophin immunohistochemistry
Frozen sections, 7 m thick, of diaphragm and lingual mus-
cles were cut and Wxed in 1:1 v/v acetone–methanol at 4°C
for 5 min. The sections were Wrst blocked at room tempera-
ture for 1 h in 0.01 M phosphate-buVered saline, pH 7.4,
containing 5% goat normal serum (G-9023; Sigma-Aldrich
Japan) (PBSS). They were incubated overnight at 4°C with
rabbit anti-utrophin antibody (1: 200; H-300; Santa Cruz
Biotechnology, Santa Cruz, California, USA) in PBSS, fol-
lowed by incubation at room temperature for 2 h with goat
anti-rabbit IgG conjugated with Alexa Fluor 568 (1: 1,000;
Molecular Probes, Eugene, Oregon, USA). The sections123
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Laboratories, Burlingame, California, USA) and sealed
with nail varnish. Fluorescence images of the immuno-
stained tissues excited at 568 nm were captured using a
confocal laser-scanning microscope as described previ-
ously. Cell nuclei in some sections immunostained for utro-
phin were subsequently labelled for 30 min with 1 g/ml
Hoechst 33258 (Nacalai Tesque, Kyoto, Japan) in 0.1 M
Tris–HCl buVer, pH 7.4 (Nakae et al. 2001). These sections
were also mounted in Vectashield mounting medium and
sealed with nail varnish. Fluorescence images of the dou-
ble-labelled sections excited simultaneously at 408 and
543 nm were captured in a Nikon confocal laser-scanning
microscope (C1si; Tokyo, Japan). All Xuorescence images
were reconstructed from a stack of 16 consecutive confocal
planes (z-stack).
Quantitative determination of utrophin expression using 
Western blotting
Diaphragm muscles were removed from three mice from
the C57 + saline group, three from the C57 + EGCG group,
four from the mdx + saline group and four from the
mdx + EGCG group. Each diaphragm muscle was
quenched immediately in a microtube cooled with liquid
nitrogen and stored at ¡80°C until use. The frozen muscle
was ground to a powder in liquid nitrogen in a mortar. The
tissue powder was homogenised in ice-cold PRO-PREP
(iNtRON Biotechnology, Sungnam, Korea) using a Poly-
tron (RT1300D; Kinematica AG, Littau, Switzerland) and
centrifuged at 13,000 rpm at 4°C for 5 min. The superna-
tants were used for Western blotting after determining their
protein concentrations with the Lowry method (Dc Protein
Assay Kit; BIO-RAD Laboratories, Hercules, California,
USA). SDS-gel electrophoresis followed by blotting to
PVDF membranes (Invitrolon PVDF; Invitrogen, Carlsbad,
California, USA) was performed with NuPAGE kits (Invit-
rogen), with a small modiWcation, according to the manu-
facturer’s instructions. Eighteen microgram of total protein
was loaded to each gel well in 3–8% SDS-polyacrylamide
gel (NuPAGE Tris–Acetate Gel; Invitrogen). A molecular
weight marker (HiMark HMW Standard; Invitrogen) was
also loaded. After electrophoresis, the gel Wlm was cut into
two halves. One half was used for quantifying the relative
amount of protein loaded in each well by staining with
Coomassie Brilliant Blue G-250 (SimplyBlue SafeStain;
Invitrogen). The other half was used for immunoblotting
for utrophin. Proteins in the half-gel Wlm were blotted to
PVDF membrane. The membrane was Wrst blocked at room
temperature for 4 h in 5% skim milk (ECL Advance West-
ern Blotting Detection Kit; Amersham Biosciences, Buck-
inghamshire, UK) in 0.01 M phosphate-buVered saline, pH
7.4, containing 0.1% Tween-20 (for molecular biology;
Sigma-Aldrich) (PBST), and then incubated overnight at
4°C with rabbit anti-utrophin antibody (1: 500; H-300;
Santa Cruz Biotechnology) and subsequently with goat
anti-rabbit IgG conjugated with horseradish peroxidase at
room temperature for 1 h (ECL Plus Western Blotting
Reagent Pack; Amersham Biosciences). After rinsing the
PVDF membrane thoroughly in PBST, the utrophin immuno-
complex was detected with a substrate for chemolumi-
nescence (Lumigen TMA-6; Amersham Biosciences). The
protein bands in all electrophoretic and immunoblotting
patterns were quantiWed using a personal computer and
ImageJ version 1.34s software (NIH) and KaleidaGraph
version 3.6.3 software (Hulinks, Tokyo, Japan).
Quantitative determination of utrophin mRNA 
using real-time RT-PCR
Diaphragm muscles were removed from three C57 + saline
mice, three mice from the C57 + EGCG group, four from
the mdx + saline group and four from the mdx + EGCG
group. They were quenched as described for Western blot-
ting in the previous paragraph and stored at ¡80°C until use.
Using the RNeasy Fibrous Tissue Mini Kit (Qiagen, Tokyo,
Japan), total RNA was extracted from the powder of the tis-
sue prepared as described for Western blotting and stored at
¡80°C. cDNA was prepared by reverse transcription (RT)
using the total RNA, random hexamers and the GeneAmp
RNA PCR kit (Applied Biosystems, Foster City, California,
USA). The reaction mixture was incubated at 45°C for
15 min, then 99°C for 5 min, and Wnally at 5°C for 5 min
and stored at ¡80°C before use. Polymerase chain reactions
(PCR) were carried out in a real-time PCR system (7500;
Applied Biosystems) using a reverse transcription mixture
containing cDNA, a utrophin primer (Mm00810176(s1;
Applied Biosystems), a ribosomal protein S18 primer
(Mm00507222(s1; Applied Biosystems) as an endogenous
control, and TaqMan Universal PCR Master Mix (Applied
Biosystems), according to the manufacturer’s instructions.
First, uracil N-glycosylase contained in the reaction mixture
was activated at 50°C for 2 min. Then, AmpliTaq Gold acti-
vation and denaturation of uracil N-glycosylase was carried
out by incubating the mixture at 95°C for 10 min. Each 40
cycles consisted of denaturation at 95°C for 15 s and anneal-
ing and extension of the primer at 60°C for 1 min. No PCR
products were detected in the negative controls of the ampli-
Wcation in which the reverse transcription mixtures were
replaced with RNase-free water. The relative amounts of
utrophin and ribosomal protein S18 transcripts were deter-
mined in the linear ranges of ampliWcations. The relative
amount of utrophin mRNA was expressed as the ratio of the
relative amount of utrophin transcripts to that of ribosomal
protein S18 transcripts, in the same sample. The RT-PCR
was repeated 2–3£ for each sample.123
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Data were expressed as means § SEM. Student’s t test was
used to test statistical signiWcances between two means.
The data for four groups were also subjected to Bonfer-
roni’s and ScheVe’s multiple t tests using SPSS software.
SigniWcance levels obtained with Student’s, Bonferroni’s
and ScheVe’s tests are denoted by the symbols P, PB and
PS, respectively. They were considered signiWcant at
P < 0.05.
Results
EVects of EGCG treatment on body weights
The EGCG treatment had no signiWcant eVects on the mean
body weights of either normal (P > 0.1, PB > 0.9, PS > 0.5)
or mdx mice (P > 0.9, PB > 0.9, PS > 0.6) compared to the
corresponding controls injected with saline (Fig. 1). The
mean body weight of male mice was 3.9–5.3 g higher than
that of female mice in each experimental group (P < 0.01).
EVects of EGCG treatment on serum creatine 
kinase activities
As shown in Fig. 2, the mean activity of serum creatine
kinase in 8-week-old mdx control mice
(23,315 § 2,845 IU/l) was about 21£ higher than that of
age-matched C57 normal control mice (1,125 § 406 IU/l).
EGCG injection into mdx mice after birth signiWcantly
reduced the activity by about 75% (P < 0.001, PB < 0.001,
PS < 0.001). The mean activity (6,670 § 996 IU/l) was
similar to, and not signiWcantly diVerent from (P > 0.1,
PB > 0.5, PS > 0.3), that of the normal mice treated with
EGCG (2,895 § 994 IU/l). However, EGCG had no signiW-
cant eVect on the activity in normal C57 mice (P > 0.2,
PB > 0.9, PS > 0.9).
EVects of EGCG treatment on muscle oxidative stress 
and histology
The eVects of EGCG treatment on the accumulation of an
oxidative stress marker, lipofuscin, in diaphragm and
soleus muscles are illustrated in Fig. 3. This shows qualita-
tively that the number of yellow or orange Xuorescent lipo-
fuscin granules in both muscles is noticeably much less
compared to those in untreated mdx controls. Quantita-
tively, the mean numbers of lipofuscin granules or clumps
per unit volume of tissue were reduced signiWcantly by
53% (P < 0.005) and 41% (P < 0.05) in diaphragm and
soleus muscles, respectively (Fig. 4).
The typical histological appearances of diaphragm and
soleus muscles in 8-week-old mdx mice treated with saline
alone compared to those of mdx mice given EGCG are
shown in Fig. 5a, b (diaphragm) and Fig. 5c, d (soleus),
respectively. Qualitatively, fewer necrotic muscle Wbres
and less connective tissue were seen in the muscles of
treated mice compared to those seen in control mice. In
contrast, there were more histologically normal muscle
Wbres. Quantitatively, the EGCG treatment reduced the
Fig. 1 Mean body weights (columns) and SEMs (bars) of 8-week-old
mice after continuous treatment with EGCG or saline from birth
(n = 8–15). The diVerences of the mean weights between the saline and
EGCG treatments are not signiWcant for either males (black columns)
or females (white columns) of mdx (P > 0.9, PB > 0.9, PS > 0.6) and
C57 normal (P > 0.1, PB > 0.9, PS > 0.5) mice. However, the diVer-
ences between males and females in each experimental group are sig-
niWcant (P < 0.01)
Fig. 2 Mean serum creatine kinase (CK) activities (columns) and
SEMs (bars) of 8-week-old mdx and C57 normal mice after continuous
treatment with saline or EGCG from birth. EGCG treatment reduces
the initial, very high mean activity in mdx mice, 21£ that of normal
C57 control mice, by about 75%, close to the level of EGCG-treated
normal mice. EGCG does not signiWcantly alter the low activity in nor-
mal mice. * P < 0.001, * PB < 0.001, * PS < 0.001123
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of histologically normal muscle Wbres. These changes are
shown quantitatively in Fig. 6. In mdx diaphragm muscles,
EGCG increased the mean relative area occupied by histo-
logically normal muscle Wbres almost 2-fold from
24.7 § 2.0% to 46.9 § 5.1% (P < 0.01) compared to that in
saline-treated mdx mice but reduced the relative areas of
connective tissue by 41%, from 37.2 § 3.6% to
22.1 § 1.9% (P < 0.01), and of necrotic muscle Wbres by
93%, from 9.6 § 3.7% to 0.7 § 0.2% (P < 0.05). In con-
trast, the relative percentage areas of muscle Wbres with
central nuclei showed no signiWcant change (P > 0.8)
between control (28.5 § 5.8%) and EGCG-treated samples
(30.4 § 4.9%). In mdx soleus muscles, EGCG treatment led
to a 1.5-fold increase in the mean relative area of histologi-
cally normal muscle Wbres from 20.8 § 3.5% to
31.2 § 1.8% (P < 0.05) but reduced the areas occupied by
necrotic muscle Wbres by 95% from 15.3 § 4.7% to
0.740 § 0.575% (P < 0.01). However, the relative percent-
age areas occupied by regenerating or regenerated muscle
Wbres with central nuclei showed no signiWcant changes
(P > 0.05) between control (40.3 § 6.8%) and test samples
(49.1 § 3.2%). Similarly, the relative areas of connective
tissue were not signiWcantly diVerent (P > 0.05) in control
(23.6 § 4.6%) and test samples (18.9 § 2.5%).
Fig. 3 Upper Wgure: confocal 
Xuorescence images of sections 
of mdx diaphragm (a) and soleus 
(c) muscles containing numer-
ous yellow or orange autoXuo-
rescent lipofuscin (LF) granules 
after treatment with saline com-
pared to their sparsity in the cor-
responding muscles after EGCG 
treatment (lower Wgure, b, d for 
diaphragm and soleus, respec-
tively). Bars = 50 m
Fig. 4 Mean numbers (columns) § SEMs (bars) of lipofuscin gran-
ules or clumps per unit volume in diaphragm (black columns) and so-
leus muscles (white columns) in mdx mice treated with saline or EGCG
for 8 weeks after birth. The EGCG treatment reduced the numbers by
53 and 41% in diaphragm and soleus muscles, respectively. * P < 0.05,
** P < 0.005 versus control values123
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liver and kidney at the light microscopical level after
EGCG treatment in either 8-week-old mdx mice or C57
normal mice.
EVects of EGCG treatment on muscle contraction
The mean maximum isometric tetanic force
(0.49 § 0.12 N/cm2) and T1/2max (50 § 13 s), the mean time
Fig. 5 Histology of diaphragm muscles of 8-week-old mdx mice with-
out (a) and after (b) EGCG treatment, and of soleus in untreated (c) and
treated (d) mdx mice. The untreated mice received saline only. Haema-
toxylin and eosin. Note the change towards normal histology in both
muscles of the EGCG-treated mice: there is much less muscle necrosis
(arrowheads) and replacement by connective tissue (arrows) in the
EGCG-treated mice (b, d) compared to that seen in the corresponding
muscles of the saline-treated mdx mice (a, c). Bars = 100 m
Fig. 6 Quantitative changes in the histology of diaphragm (a) and so-
leus (b) muscles of 8-week-old mdx mice after EGCG treatment. The
columns are the mean relative areas (expressed as percentages of the
total observed cross-section area) occupied by histologically normal
Wbres (black columns), muscle Wbres containing central nuclei (grey
columns), necrotic muscle Wbres (dotted columns) and connective tis-
sue (white columns). The bars are SEMs. In the diaphragm muscles of
EGCG-treated mice, the mean normal muscle Wbre area increases
about two-fold but the connective tissue and necrotic muscle areas are
signiWcantly reduced by about 41 and 93%, respectively, compared to
those in the corresponding saline-treated controls (a). However, the
mean percentage area of muscle Wbres with central nuclei is not signiW-
cantly altered. * P < 0.05, ** P < 0.01 versus control values. In soleus
muscles of EGCG-treated mdx mice, the mean normal muscle area in-
creases about 1.5-fold but the necrotic muscle Wbre area decreases by
95%, compared to those in the corresponding saline-treated controls
(b). Both changes are signiWcant. In contrast, there is no signiWcant
change in the mean percentage areas of muscle Wbres with central
nuclei and the connective tissue. * P < 0.05, ** P < 0.01 versus control
values123
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treated 8-week-old mdx mice were, respectively, 31%
(P < 0.001, PB < 0.01, PS < 0.009) and 48% (P < 0.01,
PB < 0.01, PS < 0.009) of those of age-matched normal
controls (1.6 § 0.3 N/cm2, 103 § 9 s) (Fig. 7). EGCG
treatment for 8 weeks after birth did not signiWcantly aVect
the mean maximum intensities of the speciWc isometric
tetanic force of mdx soleus muscles showing the mean
value 0.79 § 0.19 N/cm2 (P > 0.2, PB > 0.9, PS > 0.7). In
contrast, T1/2max of mdx muscles increased 1.9-fold
(94 § 7 s) (P < 0.01, PB < 0.01, PS < 0.02), reaching
almost the level of EGCG-treated normal mice
(101 § 8 sec). EGCG treatment did not signiWcantly alter
the isometric contraction of normal soleus muscle (P > 0.5,
PB > 0.9, PS > 0.8).
EVects of EGCG treatment on utrophin expression
In the diaphragm muscles of 8-week-old normal mice
injected with physiological saline, utrophin was mostly
localised in neuromuscular junctions, blood vessels and
peripheral nerves (Fig. 8a–c). None was observed in the
extrasynaptic sarcolemma. In contrast, in age-matched mdx
diaphragm muscles from saline-treated controls, utrophin
was localised predominantly on the extrasynaptic sarco-
lemma along the entire length of immature central-nucle-
ated basophilic myoWbres (Fig. 8d–g). As these cells
matured, utrophin gradually decreased and disappeared on
the extrasynaptic sarcolemma (Fig. 8d–g). However,
EGCG treatment of mdx mice increased the amount of utro-
phin on the extrasynaptic sarcolemma not only in immature
muscle cells but also in mature muscle cells (Fig. 8h–j).
In lingual muscles, unlike the changes observed in dia-
phragm muscles, very few regenerated muscle Wbres with
central nuclei were seen in mdx mice treated with either
EGCG or physiological saline (Fig. 9c, g). Necrotic lesions
were also rarely observed. EGCG treatment elevated utro-
phin levels on the extrasynaptic sarcolemma along the
entire length of mdx lingual muscle Wbres (Fig. 9). Utrophin
expression in blood vessels, nerve Wbres and stratiWed squa-
mous epithelia in the lingual muscle of mdx mice also
increased after EGCG treatment.
QuantiWcation of the expression bands of full-length
utrophin (identiWed as the 395 kDa protein) obtained after
typical SDS-gel electrophoresis and Western blotting of
diaphragm extracts are shown in Fig. 10. The mean amount
of utrophin formed was signiWcantly higher by 18% in mdx
control diaphragm muscles than in C57 controls (P < 0.001,
PB < 0.005, PS < 0.006). The EGCG treatment resulted in a
signiWcant increase of utrophin over these base levels by
17% (P < 0.01, PB < 0.003, PS < 0.004) and 14% (P < 0.01,
PB < 0.02, PS < 0.03) in mdx and C57 diaphragm muscles,
respectively (Fig. 10).
EVects of EGCG treatment on utrophin mRNA expression
Figure 10 also shows the eVects of the EGCG treatment on
the relative expression of mRNA determined as ratios of
utrophin mRNA/ribosomal protein S18 mRNA as an
endogenous control. The mean relative expression of utro-
phin mRNA in diaphragm muscles ranged from 0.748 to
0.913 in the test and control groups of mdx and normal
mice, but the eVects of EGCG were not signiWcant in mdx
(P > 0.9, PB > 0.9, PS > 0.9) or normal C57 (P > 0.2,
PB > 0.9, PS > 0.6) muscles.
Discussion
When the principal active component of green tea, epigallo-
catechin-3-gallate (EGCG) is injected 4£ a week from
birth at a dose of 5 mg/kg body weight for 8 weeks into
either normal or mdx mice, it has neither any eVect on their
body weights (Fig. 1), in agreement with previous reports
(Goodin and Rosengren 2003; Dorchies et al. 2006), nor
any eVect on the histology of their livers and kidneys, indi-
cating that it is not toxic at this dosage. However, when
administered in this way, EGCG limits, and possibly
delays, the onset of pathological damage in the muscles of
Fig. 7 Isometric tetanic contractions of soleus muscles of C57 and
mdx mice treated continuously with saline (controls) or EGCG for
8 weeks after birth. Each column and bar is the mean and SEM, respec-
tively. The mean maximum speciWc tetanic force (white columns) and
T1/2max, the mean time for this force to fall by a half (black columns),
of isolated soleus muscles from saline-treated mdx control mice were
less than half of those of corresponding age-matched C57 normal con-
trols. The EGCG treatment signiWcantly increased T1/2max of mdx sole-
us muscles 1.9-fold to almost the level of normal mice treated with
EGCG, but did not signiWcantly increase the maximum tetanic force.
EGCG did not signiWcantly aVect the function of normal C57 soleus
muscles (P > 0.5, PB > 0.9, PS > 0.8). * P < 0.01, * PB < 0.01,
* PS < 0.02123
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First, the activity of serum creatine kinase, a marker of
sarcolemmal damage, is reduced to almost normal levels
(Fig. 2). Second, oxidative stress in muscle Wbres is
reduced as shown by the approximately 50% decrease in
the number of lipofuscin granules that are formed (Figs. 3,
4). Third, the histology of both the fast-contracting dia-
phragm muscle and the slow-contracting soleus is
improved and closely resembles that of normal muscle
(Figs. 5, 6). Fourth, the mean time for the maximum tetanic
force to fall by a half (T1/2max) increases in mdx soleus mus-
cles to an almost normal level (Fig. 7). Fifth, the amount of
utrophin formed in mdx diaphragm muscle is signiWcantly
increased by 17% (Figs. 8–10).
Our Wnding of a signiWcantly lower number of lipofuscin
granules in the muscles of EGCG-treated mdx mice sub-
stantiates our working hypothesis proposed earlier (Nakae
et al. 2004) that administration of an antioxidant such as
Fig. 8 Increase in the level of extrasynaptic sarcolemmal utrophin in
diaphragm muscles of 8-week-old mdx mice treated with EGCG for
8 weeks. a–c C57 + saline. d–g Mdx + saline. h–j Mdx + EGCG. b, e,
i Confocal Xuorescence images showing utrophin localisation com-
pared to serial cross-sections stained with haematoxylin and eosin (a,
d and h, respectively). c Higher magniWcation image of b. f, g Higher
magniWcations of another area in the same section as d and e, respec-
tively. j Confocal image of a serial section double-stained for utrophin
and cell nuclei. In C57 normal muscles, most utrophin seems to be
present at neuromuscular junctions on the sarcolemma of muscle Wbres
(b, c). Blood vessels (BV in a–c) also contain utrophin. In mdx saline-
treated control muscle, utrophin is abundantly localised on the sarco-
lemma along the entire length in regenerating immature muscle cells
(arrows in f, g) with central nuclei and basophilic cytoplasm but disap-
pears as the muscle cells mature (arrowheads in d–g). EGCG treatment
of mdx mice enhances the extrasynaptic sarcolemmal level of utrophin
in mature muscle Wbres (arrowheads in h–j). Compare with Fig. 9.
Bars = 50 m123
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for how long this protection can be maintained has still to
be established.
Other reports (e.g. Messina et al. 2006; Burdi et al.
2006) of improvements in muscle function and histopathol-
ogy in mdx mice treated with other antioxidants, such as
IRFI-042 or BN 82270, support our Wndings. Both EGCG
(Fig. 2) and IRFI-042 reduce the mean activity of serum
creatine kinase by about 75% in mdx mice. This lowering is
greater than the reductions observed after heregulin (about
50%, Krag et al. 2004) or L-arginine (about 60%, Voisin
et al. 2005) administration reported previously. That the
reduction of creatine kinase activity in our investigation
after EGCG treatment is not due to the inhibition of the
activity by EGCG is conWrmed by the non-signiWcant
diVerence between the activities in normal mice injected
with EGCG and those given saline only (Fig. 2).
The weekly dosage of EGCG administered in our inves-
tigation was 20 mg/kg body weight, equivalent to an aver-
age daily dosage of 2.86 mg/kg body weight. This is much
less than the intraperitoneal dosage of 25 mg/kg body
weight administered every day for 1 week by Goodin and
Rosengren (2003), who showed that EGCG had no toxic
eVects in mice. It is also considerably lower than the aver-
age dosage of 150 mg EGCG/kg body weight per day con-
sumed in food pellets eaten by mice reported by Dorchies
et al. (2006). However, according to Lambert et al. (2006a),
diVerent routes of EGCG administration lead to consider-
ably diVerent concentrations and half-lives of free EGCG in
plasma. They found that oral or intragastric administration
of 75 mg EGCG/kg body weight in mice gave a maximum
plasma concentration of about 130 ng EGCG/ml and a half-
life of just over an hour, whereas when EGCG is applied
transdermally as a topical gel at a dose of 50 mg/kg body
weight, its maximum plasma concentration is about 45 ng/
ml, has a very much longer half-life of 94 h, and is mostly
in a bioactive free form. In contrast, when EGCG is adminis-
tered orally, most of it becomes methylated, glucuronidated
and sulphated, thus reducing its bioavailability (Lambert
et al. 2003; Lu et al. 2003). Assuming that there is an
approximate linear relationship between dosage and plasma
concentration (Lambert et al. 2006b), and that transdermal
absorption yields approximately the same delivery dosage
as subcutaneous injection, the subcutaneous administration
Fig. 9 Increase in the extrasynaptic sarcolemmal level of utrophin in
lingual muscles in 8-week-old mdx mice after treatment with EGCG
from birth. a–d Mdx + saline. e–h Mdx + EGCG. b, d, f, h Confocal
images of serial cross-sections immunostained for utrophin, corre-
sponding to the serial sections stained with haematoxylin and eosin
shown in a, c, e, and g, respectively. Necrotic lesions are sparse in lin-
gual muscles of mdx mice treated with either saline or EGCG; regen-
erating muscle cells with central nuclei are rarely seen (arrows in c, d,
g, h). Interestingly, the EGCG treatment results in an enhanced extra-
synaptic level of utrophin in mdx lingual muscles showing no serious
dystrophic damage. More utrophin is also present in blood vessels
(BV), peripheral nerves (N in b, f) and stratiWed squamous epithelia in
the tongues of EGCG-treated mice (f) than in saline-treated controls
(b). Bars = 50 m123
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experiments would give a fairly constant concentration of
EGCG in the blood of roughly 4.5 ng/ml over 2–3 days. In
contrast, if mice consumed 150 mg EGCG/kg body weight
orally all at once, their plasma concentration would be
approximately 260 ng/ml, about 60£ higher than in our
experiments, but the EGCG would be rapidly lost. In prac-
tice, mice would only eat on average about 6 mg EGCG/kg
body weight per hour, corresponding to a plasma concen-
tration of about 10 ng/ml, approximately twice the com-
puted concentration in our study. However, in view of the
approximations and assumptions underlying these calcula-
tions, the most that can be concluded is that the eVective
dose and bioavailability of EGCG in our experiments are of
the same order as those yielded by the oral route employed
by Ruegg and his colleagues (Dorchies et al. 2006),
although subcutaneous administration allows a more pre-
cise control of the dosage in individual animals.
In their study, Dorchies et al. (2006) found that EGCG
reduces the oxidative potential of the plasma in treated mdx
mice, delayed muscle necrosis in the extensor digitorum
longus, and improves quantitatively the functions of mdx
triceps surae muscles. Our Wndings corroborate their obser-
vations. In contrast, these authors reported that the necrotic
lesions in soleus muscles were not signiWcantly reduced by
either EGCG or green tea extract administered orally to
mdx mice for 1 or 5 weeks from the age of 3 weeks. How-
ever, as shown in the present study, subcutaneous injection
of 5 mg/kg body weight EGCG into mdx mice for 8 weeks
after birth signiWcantly increased the relative percentage
area of histologically normal muscle Wbres and reduced that
of necrotic muscle Wbres (Figs. 5, 6), and prolonged the
times of the maximum tetanic force of soleus muscles to
fall by a half to almost normal levels (Fig. 7).
EGCG limited the onset of muscular dystrophy features
more eVectively in diaphragm muscle. Diaphragm muscle
is a good one for studying the pathology of DMD (Stedman
et al. 1991). We selected it not only for this reason but also
because previously we found that the diaphragm muscles of
mdx mice had already accumulated the products of oxida-
tive damage, lipofuscin granules, by the time they were 4
weeks old (Nakae et al. 2004).
At present, one can only conjecture the diVerent
responses to EGCG of a slow-contracting muscle such as
the soleus and a fast-contracting muscle such as the dia-
phragm reported here, or the soleus and extensor digitorum
longus or triceps surae reported by Dorchies et al. (2006).
One explanation proposed by these authors is that the
diVerent susceptibilities of the two muscle types may be
partly due to their diVerent Wbre-type compositions. The
mouse diaphragm and EDL consist entirely of fatiguable
fast-twitch type II Wbres (EDL, about 80% type IIB and
20% type IIX; Agbulut et al. 1996) whereas the soleus is
mostly composed of type I Wbres. Type IIB Wbres appear to
be more susceptible to cell death, presumably by free radi-
cals such as ·O2, than other Wbre types (Rando 2002). If this
is so, it is not surprising that muscles containing a prepon-
derance of type IIB Wbres are better protected by a free-
radical scavenger or an antioxidant such as EGCG than
muscles consisting mostly of type I Wbres.
The signiWcance of the increased amounts of utrophin
that we observed after EGCG treatment is less clear. We
observed that utrophin localises in a complex pattern to
neuromuscular and myotendinous junctions, blood vessels,
and peripheral nerves in mature normal and dystrophic
muscles (Figs. 8, 9), conWrming what others have reported
previously (Khurana et al. 1991; Ohlendieck et al. 1991;
Takemitsu et al. 1991; Clerk et al. 1993; Weir et al. 2002,
2004; Sewry et al. 2005). Utrophin is also strongly
expressed in immature normal and dystrophic muscle cells
along the entire length of their sarcolemma but the amount
declines with maturation and ageing of muscle cells (Khur-
ana et al. 1991; Takemitsu et al. 1991; Clerk et al. 1993;
Sewry et al. 2005). This is illustrated in Figs. 8 and 9. We
also observed that the level of utrophin is higher in mature
mdx dystrophic muscles than in age-matched normal con-
trols, illustrated in Figs. 8 and 10, and in agreement with
previous reports (Gramolini et al. 1998; Weir et al. 2002,
Fig. 10 Levels of utrophin protein and utrophin mRNA in diaphragm
muscles in 8-week-old mdx and normal mice after treatment with
EGCG or saline. These were determined as described in “Materials and
methods”. Each column and bar indicates the mean and SEM, respec-
tively. The relative mean level (black column) of utrophin (taking that
in C57 saline-treated mice as 1.0) was signiWcantly higher by 18% in
mdx saline-treated controls than in normal C57 controls. EGCG treat-
ment increased the utrophin level signiWcantly by 17 and 14% in mdx
and C57 diaphragm muscles, respectively. In contrast, EGCG has no
eVect (P > 0.2, PB > 0.9, PS > 0.6) on the mean relative expression of
utrophin mRNA (white columns) determined in diaphragm muscles in
mdx and normal C57 mice using a quantitative real-time RT-PCR as-
say. * P < 0.01, * PB < 0.02, * PS < 0.03; ** P < 0.01, ** PB < 0.003,
** PS < 0.004; *** P < 0.001, *** PB < 0.005, *** PS < 0.006123
500 Histochem Cell Biol (2008) 129:489–5012004). Our observations are the Wrst evidence that EGCG
treatment elevates utrophin levels on the extrasynaptic sar-
colemma not only in dystrophic muscles but also in normal
muscles. The increase in the utrophin levels is not due to
muscle regeneration since mdx lingual muscles, which do
not exhibit focal degeneration and regeneration at 8 weeks
of age, also show this phenomenon (Fig. 9). The increased
level persists considerably in mature muscle Wbres in dys-
trophic muscles (Figs. 8, 9). However, the 17% increase in
utrophin levels induced by EGCG that we observed in dia-
phragm muscle (Fig. 10) is modest, although signiWcant
(P < 0.01), and is smaller than that induced by heregulin
(170% in tibialis anterior muscle, Krag et al. 2004) or by L-
arginine (60% in diaphragm muscle, Voisin et al. 2005;
24% in EDL muscle, Barton et al. 2005). However, as
EGCG does not elevate the steady-state utrophin mRNA
levels in diaphragm muscles in mdx mice (Fig. 10), the
higher levels of utrophin protein are not due to its enhanced
expression. Further, as EGCG also signiWcantly increases
utrophin levels in diaphragm muscles of normal mice, by
about 14%, 3% less than in the corresponding dystrophic
muscle (Fig. 10), and the contraction properties of isolated
normal soleus muscles are not signiWcantly changed by our
EGCG treatment regime (Fig. 7), the observed utrophin
increases are not due to a speciWc stimulation by EGCG per
se but are incidental.
In conclusion, our study corroborates other recent stud-
ies that EGCG is eVective for limiting the onset of muscular
dystrophy in newborn mdx mice without causing side
eVects, but the optimal dosage, administration route and the
latest age at which treatment can be started in order to pre-
vent muscle Wbre necrosis and regeneration from occurring
have still to be established. We are currently investigating
whether EGCG has a beneWcial eVect when given to older
mice when the myoWbre necrosis–regeneration cycles have
begun in earnest.
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